This study reveals a CD4+ T cell subset-centered immunoregulatory network in DCM, identifying novel diagnostic biomarkers and druggable targets to guide precision immunomodulatory strategies for DCM management. The gene discussed is CD4; the disease is familial dilated cardiomyopathy.